Mouse CD8alpha+ DCs and Human BDCA3+ DCs Are Major Producers of IFN-lambda in Response to Poly IC
Overview
General Medicine
Authors
Affiliations
Polyinosinic:polycytidylic acid (poly IC), a double-stranded RNA, is an effective adjuvant in vivo. IFN-λs (also termed IL-28/29) are potent immunomodulatory and antiviral cytokines. We demonstrate that poly IC injection in vivo induces large amounts of IFN-λ, which depended on hematopoietic cells and the presence of TLR3 (Toll-like receptor 3), IRF3 (IFN regulatory factor 3), IRF7, IFN-I receptor, Fms-related tyrosine kinase 3 ligand (FL), and IRF8 but not on MyD88 (myeloid differentiation factor 88), Rig-like helicases, or lymphocytes. Upon poly IC injection in vivo, the IFN-λ production by splenocytes segregated with cells phenotypically resembling CD8α(+) conventional dendritic cells (DCs [cDCs]). In vitro experiments revealed that CD8α(+) cDCs were the major producers of IFN-λ in response to poly IC, whereas both CD8α(+) cDCs and plasmacytoid DCs produced large amounts of IFN-λ in response to HSV-1 or parapoxvirus. The nature of the stimulus and the cytokine milieu determined whether CD8α(+) cDCs produced IFN-λ or IL-12p70. Human DCs expressing BDCA3 (CD141), which is considered to be the human counterpart of murine CD8α(+) DCs, also produced large amounts of IFN-λ upon poly IC stimulation. Thus, IFN-λ production in response to poly IC is a novel function of mouse CD8α(+) cDCs and their human equivalents.
Colaco M, Cruz M, de Almeida L, Borges O Pharmaceutics. 2024; 16(10).
PMID: 39458637 PMC: 11510408. DOI: 10.3390/pharmaceutics16101308.
Trial watch: anticancer vaccination with dendritic cells.
Borges F, Laureano R, Vanmeerbeek I, Sprooten J, Demeulenaere O, Govaerts J Oncoimmunology. 2024; 13(1):2412876.
PMID: 39398476 PMC: 11469433. DOI: 10.1080/2162402X.2024.2412876.
Wang B, Zhou B, Chen J, Sun X, Yang W, Yang T J Immunother Cancer. 2024; 12(4).
PMID: 38589249 PMC: 11015199. DOI: 10.1136/jitc-2023-007808.
Liu Y, Jin S, Zhang S, Xia T, Liao Y, Pan R Front Immunol. 2024; 15:1338096.
PMID: 38495892 PMC: 10940417. DOI: 10.3389/fimmu.2024.1338096.
Dendritic Cells as a Therapeutic Strategy in Acute Myeloid Leukemia: Vaccines.
Palomares F, Pina A, Dakhaoui H, Leiva-Castro C, Munera-Rodriguez A, Cejudo-Guillen M Vaccines (Basel). 2024; 12(2).
PMID: 38400148 PMC: 10891551. DOI: 10.3390/vaccines12020165.